GSK receives complete response letter for MenHibrix
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline has received a complete response letter from the US FDA for its combined meningococcal disease (serogroups C and Y) and Haemophilus influenzae type b (Hib) conjugated vaccine candidate MenHibrix.